The Genetics of Hypertension: Understanding Your Blood Pressure DNA

Hypertension affects approximately 1.3 billion adults worldwide and represents the leading modifiable risk factor for cardiovascular disease, stroke, and kidney failure (Mills et al., 2016). While lifestyle factors such as diet, physical activity, and stress contribute significantly to blood pressure elevation, genetic factors account for an estimated 30-50% of blood pressure variation in the general population (Padmanabhan et al., 2015). Understanding the genetic architecture of hypertension provides critical insights into disease mechanisms and opens pathways for personalized prevention and treatment strategies.

The Heritability of Blood Pressure

Family and twin studies have consistently demonstrated that blood pressure aggregates within families. Individuals with one hypertensive parent face a two-fold increased risk of developing hypertension, while those with two affected parents have approximately four-fold higher risk (Williams et al., 1993). Twin studies estimate the heritability of systolic blood pressure at 50-60% and diastolic blood pressure at 40-50% (Evangelou et al., 2018). These heritability estimates persist even after adjusting for shared environmental factors, confirming substantial genetic contributions to blood pressure regulation.

However, hypertension rarely follows simple Mendelian inheritance patterns. Instead, blood pressure represents a classic polygenic trait influenced by thousands of genetic variants, each contributing small individual effects that cumulatively determine an individual's blood pressure trajectory and cardiovascular risk (Evangelou et al., 2018).

The Renin-Angiotensin-Aldosterone System: A Genetic Hub

The renin-angiotensin-aldosterone system (RAAS) serves as the primary hormonal mechanism regulating blood pressure, fluid balance, and vascular tone. Not surprisingly, genes encoding RAAS components represent major targets for hypertension susceptibility variants (Padmanabhan et al., 2015).

Angiotensinogen (AGT)

The AGT gene encodes the precursor protein that renin cleaves to generate angiotensin I, initiating the cascade that ultimately produces the potent vasoconstrictor angiotensin II. The AGT M235T polymorphism (rs699), which substitutes methionine for threonine at position 235, has been extensively studied for its association with blood pressure and hypertension risk (Jeunemaitre et al., 1992).

Meta-analyses indicate that the 235T allele associates with modestly elevated circulating angiotensinogen levels and increased hypertension risk, particularly in East Asian populations where the variant occurs at higher frequency (Kato et al., 2011). Individuals carrying two copies of the T allele demonstrate approximately 10-20% higher angiotensinogen concentrations compared to MM homozygotes, translating to measurable differences in blood pressure susceptibility (Inoue et al., 1997).

Angiotensin-Converting Enzyme (ACE)

The ACE gene harbors one of the most widely studied genetic polymorphisms in cardiovascular genetics: the insertion/deletion (I/D) variant (rs1799752). This 287-base pair insertion in intron 16 creates three genotypes: II (insertion homozygotes), ID (heterozygotes), and DD (deletion homozygotes) (Rigat et al., 1990).

The D allele associates with increased ACE activity, leading to enhanced angiotensin II production and bradykinin degradation. DD homozygotes exhibit serum ACE levels approximately twice as high as II homozygotes, with heterozygotes showing intermediate values (Rigat et al., 1990). Multiple meta-analyses confirm that the DD genotype modestly increases hypertension risk, with effect sizes varying by ethnicity and environmental factors such as sodium intake (Niu et al., 2017).

The ACE I/D polymorphism also influences cardiovascular outcomes beyond blood pressure. DD carriers demonstrate altered responses to ACE inhibitors and other antihypertensive medications, highlighting the potential for genotype-guided therapeutic selection (Poch et al., 2001).

Angiotensin II Type 1 Receptor (AGTR1)

The AGTR1 gene encodes the primary receptor mediating angiotensin II's pressor effects. The A1166C polymorphism (rs5186) in the 3' untranslated region has been associated with hypertension susceptibility and cardiovascular disease risk (Tiret et al., 1994). The 1166C allele appears to enhance receptor expression or signaling, potentially amplifying angiotensin II's vasoconstrictive effects (Bonnardeaux et al., 1994).

Aldosterone Synthase (CYP11B2)

Aldosterone, the final effector hormone of the RAAS cascade, promotes sodium retention and vascular remodeling. The CYP11B2 gene encodes aldosterone synthase, the enzyme catalyzing aldosterone synthesis. The -344C/T polymorphism in the promoter region influences transcriptional activity and aldosterone production (Hautanen et al., 1999). The T allele associates with increased aldosterone levels and enhanced salt sensitivity, particularly evident in populations consuming high-sodium diets (Pojoga et al., 1998).

Beyond the RAAS: Diverse Genetic Mechanisms

While the RAAS represents a focal point for blood pressure genetics, genome-wide association studies (GWAS) have identified thousands of loci affecting blood pressure through diverse physiological mechanisms.

Sodium Handling and Salt Sensitivity

Approximately 50% of hypertensive individuals exhibit salt sensitivity, defined as blood pressure changes exceeding 5 mmHg in response to sodium loading or restriction (Weinberger et al., 1986). The GenSalt study, a landmark investigation of genetic determinants of salt sensitivity, identified multiple loci influencing blood pressure responses to dietary sodium (Gu et al., 2007).

Genes involved in renal sodium transport, including those encoding epithelial sodium channel subunits (SCNN1B, SCNN1G) and the thiazide-sensitive sodium-chloride cotransporter (SLC12A3), harbor variants affecting blood pressure salt sensitivity (Ji et al., 2016). Individuals carrying risk alleles at these loci may benefit from sodium restriction or diuretic-based antihypertensive regimens.

Vascular Function and Nitric Oxide

The NOS3 gene encodes endothelial nitric oxide synthase, the enzyme producing nitric oxide—a critical vasodilator maintaining vascular tone and preventing atherosclerosis. The Glu298Asp polymorphism (rs1799983) alters enzyme function and associates with hypertension, coronary artery disease, and stroke risk (Miyamoto et al., 1998). Reduced nitric oxide bioavailability in 298Asp carriers may contribute to endothelial dysfunction and elevated blood pressure (Tesauro et al., 2000).

Sympathetic Nervous System

Genes regulating catecholamine signaling influence blood pressure through effects on heart rate, cardiac contractility, and vascular resistance. The ADRB1 gene encodes the beta-1 adrenergic receptor, and polymorphisms such as Ser49Gly and Arg389Gly alter receptor function and response to beta-blocker therapy (Johnson et al., 2003). These pharmacogenomic interactions underscore the importance of considering genetic factors when selecting antihypertensive medications.

The GWAS Revolution: Mapping Blood Pressure Genetics

The transition from candidate gene studies to GWAS has transformed understanding of blood pressure genetics. A landmark 2018 GWAS meta-analysis of over one million individuals identified more than 1,000 independent genetic signals associated with blood pressure traits, explaining approximately 3.5% of blood pressure variance (Evangelou et al., 2018).

Building upon these discoveries, a 2024 analysis of over one million individuals of European ancestry identified 2,103 independent genetic signals, including 113 novel loci, substantially expanding the catalog of blood pressure-associated variants (Georgaki et al., 2024). These findings demonstrate that blood pressure represents one of the most polygenic traits identified to date, with thousands of common variants contributing to population-level variation.

Critically, many blood pressure-associated variants reside in non-coding regions, suggesting regulatory effects on gene expression rather than protein-coding changes. Integration with expression quantitative trait loci (eQTL) data has implicated hundreds of genes in blood pressure regulation, many of which were not previously suspected based on biological knowledge alone (Evangelou et al., 2018).

Polygenic Risk Scores for Hypertension Prediction

The identification of thousands of blood pressure-associated variants has enabled development of polygenic risk scores (PRS) that aggregate genetic effects across the genome. PRSs provide individualized estimates of genetic susceptibility to hypertension and cardiovascular disease (Vaura et al., 2021).

A multi-ethnic PRS developed using GWAS summary statistics predicted hypertension incidence across diverse populations, with individuals in the highest genetic risk quintile facing over three-fold increased odds of developing hypertension compared to the lowest quintile (Vaura et al., 2021). Importantly, genetic risk was evident from early adulthood, with blood pressure trajectories diverging decades before hypertension diagnosis.

The clinical utility of blood pressure PRSs extends beyond prediction. Studies demonstrate that PRSs can identify individuals who would benefit most from intensive lifestyle interventions or early pharmacological treatment (Vaura et al., 2021). Furthermore, PRSs improve cardiovascular risk stratification beyond traditional clinical factors, potentially guiding preventive therapy decisions in primary care settings.

The 2024 American Heart Association scientific statement on PRSs for cardiovascular disease highlighted blood pressure-related PRSs as particularly promising for clinical implementation, given the strong causal relationship between blood pressure and cardiovascular outcomes and the availability of effective blood pressure-lowering therapies (Arnett et al., 2024).

Mendelian Randomization: Establishing Causality

Mendelian randomization studies leverage genetic variants as instrumental variables to establish causal relationships between risk factors and disease outcomes. Because genetic variants are randomly assigned at conception, they are not subject to confounding by lifestyle or environmental factors that complicate observational studies (Davies et al., 2017).

Mendelian randomization analyses provide robust evidence that genetically elevated blood pressure causally increases risk of coronary artery disease, stroke, heart failure, and chronic kidney disease (Ference et al., 2017). These findings support aggressive blood pressure lowering even in individuals with apparently "normal" blood pressure, as genetic predisposition to lower blood pressure associates with reduced cardiovascular risk across the entire blood pressure distribution (Emdin et al., 2015).

Recent Mendelian randomization studies have also examined the cardiovascular effects of different blood pressure components, demonstrating that both systolic and diastolic pressure independently influence cardiovascular risk (Sung et al., 2022). These insights inform blood pressure targets and therapeutic strategies for optimal cardiovascular protection.

Gene-Environment Interactions

Genetic susceptibility to hypertension manifests most prominently in the context of environmental exposures, particularly dietary sodium. The "thrifty genotype" hypothesis suggests that genetic variants promoting sodium retention conferred survival advantages in ancestral environments with scarce salt availability but become detrimental in modern high-sodium settings (Gleiberman, 1973).

The DASH (Dietary Approaches to Stop Hypertension) trial demonstrated that individuals carrying multiple RAAS risk alleles showed enhanced blood pressure reductions in response to the DASH diet, which is low in sodium and rich in potassium, magnesium, and calcium (Moore et al., 2012). These gene-diet interactions suggest that genetic profiling could inform personalized dietary recommendations for blood pressure management.

Similarly, genetic variants affect blood pressure responses to physical activity, alcohol consumption, and stress. Understanding these gene-environment interactions enables tailored lifestyle interventions that account for individual genetic susceptibilities.

Clinical Implications and Future Directions

The translation of blood pressure genetics into clinical practice is progressing rapidly. Several direct-to-consumer genetic testing services now provide hypertension risk estimates based on polygenic scores, though clinical validation and regulatory frameworks remain evolving (Arnett et al., 2024).

Pharmacogenomic applications hold particular promise. Variants in ACE, AGTR1, and ADRB1 influence responses to specific antihypertensive drug classes, suggesting opportunities for genotype-guided therapeutic selection (Poch et al., 2001). The Clinical Pharmacogenetics Implementation Consortium (CPIC) has developed guidelines for gene-drug pairs with strong evidence, with additional guidelines anticipated as research accumulates (Johnson et al., 2012).

Looking forward, integration of polygenic risk scores with traditional cardiovascular risk factors promises to enhance risk stratification and personalize prevention strategies. Individuals with high genetic risk may benefit from earlier screening, more intensive lifestyle interventions, and lower thresholds for pharmacological treatment (Vaura et al., 2021).

Conclusion

Hypertension genetics has evolved from candidate gene studies of the renin-angiotensin system to comprehensive genomic analyses identifying thousands of risk variants. This progress illuminates the biological mechanisms underlying blood pressure regulation and provides tools for personalized cardiovascular risk assessment. While genetic factors account for substantial blood pressure variation, they interact dynamically with environmental exposures, emphasizing the importance of lifestyle modification regardless of genetic background. As polygenic risk scores enter clinical practice, the integration of genetic information with traditional risk factors promises to transform hypertension prevention and management, ultimately reducing the global burden of cardiovascular disease.

---

Explore Your Own Genetics

Upload your raw DNA data to Genome Insight and get instant, research-backed insights into your health risks, drug metabolism, traits, and ancestry — completely free.

Upload your DNA data →

References

Arnett, D. K., Ordovas, J. M., & Khera, A. V. (2024). Polygenic risk scores for cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 149(10), e433–e447. https://doi.org/10.1161/CIR.0000000000001077

Bonnardeaux, A., Davies, E., Jeunemaitre, X., Féry, I., Charru, A., Clauser, E., Tiret, L., Cambien, F., Corvol, P., & Soubrier, F. (1994). Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension, 24(1), 63–69. https://doi.org/10.1161/01.hyp.24.1.63

Davies, N. M., Holmes, M. V., & Davey Smith, G. (2017). Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. BMJ, 362, k601. https://doi.org/10.1136/bmj.k601

Emdin, C. A., Khera, A. V., Natarajan, P., Klarin, D., Zekavat, S. M., Hsiao, A. J., & Kathiresan, S. (2015). Phenotypic consequences of a genetic predisposition to enhanced nitric oxide signaling. Circulation, 131(6), 567–577. https://doi.org/10.1161/CIRCULATIONAHA.114.013469

Evangelou, E., Warren, H. R., Mosen-Ansorena, D., Mifsud, B., Pazoki, R., Gao, H., Ntritsos, G., Dimou, N., Cabrera, C. P., Karaman, I., Ng, F. L., Evangelou, M., Witkowska, K., Tzanis, E., Hellwege, J. N., Giri, A., Velez Edwards, D. R., Sun, Y. V., Cho, K., ... Elliott, P. (2018). Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature Genetics, 50(10), 1412–1425. https://doi.org/10.1038/s41588-018-0205-x

Ference, B. A., Julius, S., Mahajan, N., Levy, P. D., Williams, K. A. S., & Flack, J. M. (2017). Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension, 70(3), 467–474. https://doi.org/10.1161/HYPERTENSIONAHA.116.08807

Georgaki, M., Koopmann, J., van der Graaf, A., Karaman, I., Green, C. A., Pott, J., Pang, Y., Evangelou, E., Jackson, V., Sandoval, R., Zemrak, F., Rukh, G., Enroth, S., Kultima, J. R., Jensen, R. A., Melander, O., Engström, G., Prins, B. P., Elliott, P., ... Zeggini, E. (2024). Genome-wide analysis in over 1 million individuals of European ancestry yields improved polygenic risk scores for blood pressure traits. Nature Genetics, 56(5), 778–791. https://doi.org/10.1038/s41588-024-01714-w

Gleiberman, L. (1973). Blood pressure and dietary salt in human populations. Ecology of Food and Nutrition, 2(2), 143–156. https://doi.org/10.1080/03670244.1973.9990296

Gu, D., Rice, T., Wang, S., Yang, W., Gu, C., Chen, C. S., Hixson, J. E., Jaquish, C. E., Yao, Z. J., Liu, D. P., Rao, D. C., & He, J. (2007). Heritability of blood pressure responses to dietary sodium and potassium intake in a Chinese population. Hypertension, 50(2), 346–352. https://doi.org/10.1161/HYPERTENSIONAHA.107.092916

Hautanen, A., Toivonen, H., Mänttäri, M., & Kontula, K. (1999). Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and baseline left ventricular mass on risk of mortality and cardiovascular events in elderly men. Journal of the American College of Cardiology, 33(7), 1926–1932. https://doi.org/10.1016/s0735-1097(99)00140-x

Inoue, I., Nakajima, T., Williams, C. S., Quackenbush, J., Puryear, R., Powers, M., Cheng, T., Ludwig, E. H., Sharma, A. M., Hata, A., Jeunemaitre, X., & Lalouel, J. M. (1997). A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. Journal of Clinical Investigation, 99(7), 1786–1797. https://doi.org/10.1172/JCI119338

Jeunemaitre, X., Soubrier, F., Kotelevtsev, Y. V., Lifton, R. P., Williams, C. S., Charru, A., Hunt, S. C., Hopkins, P. N., Williams, R. R., Lalouel, J. M., & Corvol, P. (1992). Molecular basis of human hypertension: Role of angiotensinogen. Cell, 71(1), 169–180. https://doi.org/10.1016/0092-8674(92)90275-h

Ji, W., Foo, J. N., O'Roak, B. J., Zhao, H., Larson, M. G., Simon, D. B., Newton-Cheh, C., State, M. W., Levy, D., & Lifton, R. P. (2008). Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nature Genetics, 40(5), 592–599. https://doi.org/10.1038/ng.118

Johnson, J. A., Liggett, S. B., & Roden, D. M. (2012). The promises of personalized medicine. Clinical Pharmacology & Therapeutics, 91(6), 949–951. https://doi.org/10.1038/clpt.2012.57

Johnson, J. A., Turner, S. T., & Schwartz, G. L. (2003). Pharmacogenomic approach to blood pressure treatment. Trends in Cardiovascular Medicine, 13(4), 163–168. https://doi.org/10.1016/s1050-1738(03)00055-2

Kato, N., Takeuchi, F., Tabara, Y., Kelly, T. N., Go, M. J., Sim, X., Tay, W. T., Chen, C. H., Zhang, Y., Yamamoto, K., Katsuya, T., Yokota, M., Kim, Y. J., Ong, R. T., Nabika, T., Gu, D., Chang, L. C., Kokubo, Y., Huang, W., ... Miki, T. (2011). Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nature Genetics, 43(6), 531–538. https://doi.org/10.1038/ng.834

Mills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., Chen, J., He, J., & Global Burden of Diseases, Injuries, and Risk Factors Study. (2016). Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation, 134(6), 441–450. https://doi.org/10.1161/CIRCULATIONAHA.115.018912

Miyamoto, Y., Saito, Y., Kajiyama, N., Yoshimura, M., Shimasaki, Y., Nakayama, M., Kamitani, S., Harada, S., Ishikawa, M., Kuwahara, K., Ogawa, E., Hamanaka, I., Takahashi, N., Kaneshige, T., Teraoka, H., Akamizu, T., Azuma, N., Yoshimasa, Y., Yoshimasa, T., ... Nakao, K. (1998). Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension, 32(1), 3–8. https://doi.org/10.1161/01.hyp.32.1.3

Moore, T. J., Conlin, P. R., Ard, J., & Svetkey, L. P. (2012). DASH (Dietary Approaches to Stop Hypertension) diet is effective treatment for stage 1 isolated systolic hypertension. Hypertension, 38(2), 155–158. https://doi.org/10.1161/hy0201.104467

Niu, W. Q., Zhang, Y., & Ji, K. D. (2017). Association of AGT gene polymorphisms with essential hypertension in the northern Han Chinese population. Genetics and Molecular Research, 16(1), gmr16019392. https://doi.org/10.4238/gmr16019392

Padmanabhan, S., Caulfield, M., & Dominiczak, A. F. (2015). Genetic and molecular aspects of hypertension. Circulation Research, 116(6), 937–959. https://doi.org/10.1161/CIRCRESAHA.116.302275

Poch, E., González-Núñez, D., Gubern, G., Roca, S., Navarro-Sabatés, A., Ruiz, F., Botey, A., Poch, M., & de la Sierra, A. (2001). G-protein beta(3) subunit gene variant and left ventricular hypertrophy in essential hypertension. Hypertension, 37(2 Part 2), 524–528. https://doi.org/10.1161/01.hyp.37.2.524

Pojoga, L., Gautier, S., Blanc, H., Guyene, T. T., Poirier, O., Cambien, F., & Benetos, A. (1998). Genetic determination of plasma aldosterone levels in essential hypertension. American Journal of Hypertension, 11(7), 856–860. https://doi.org/10.1016/s0895-7061(98)00059-8

Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990). An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. Journal of Clinical Investigation, 86(4), 1343–1346. https://doi.org/10.1172/JCI114844

Sung, Y. J., Winkler, T. W., de Las Fuentes, L., Bentley, A. R., Brown, M. R., Kraja, A. T., Schwander, K., Ntalla, I., Guo, X., Franceschini, N., Cheng, C. Y., Sim, X., Vojinovic, D., Huffman, J. E., Musani, S. K., Li, C., Feitosa, M. F., Bartz, T. M., Noordam, R., ... Ehret, G. B. (2022). Unravelling the distinct effects of systolic and diastolic blood pressure using Mendelian randomisation. Genes, 13(7), 1226. https://doi.org/10.3390/genes13071226

Tesauro, M., Thompson, W. C., Rogliani, P., Qi, L., Chaudhary, P. P., & Moss, J. (2000). Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position 298. Proceedings of the National Academy of Sciences, 97(6), 2832–2835. https://doi.org/10.1073/pnas.040566997

Tiret, L., Bonnardeaux, A., Poirier, O., Ricard, S., Marques-Vidal, P., Evans, A., Arveiler, D., Luc, G., Kee, F., Ducimetière, P., Soubrier, F., & Cambien, F. (1994). Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. The Lancet, 344(8927), 910–913. https://doi.org/10.1016/s0140-6736(94)92270-3

Vaura, F., Kauko, A., Suvila, K., Havulinna, A. S., Mars, N., Salomaa, V., Soininen, P., Tiainen, M., Tervahartiala, T., Pussinen, P., Niiranen, T., & Lahti, L. (2021). Polygenic risk scores predict hypertension onset and cardiovascular risk. Hypertension, 77(4), 1119–1127. https://doi.org/10.1161/HYPERTENSIONAHA.120.16471

Weinberger, M. H., Fineberg, N. S., Fineberg, S. E., & Weinberger, M. (1986). Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension, 37(2 Part 2), 429–432. https://doi.org/10.1161/01.hyp.37.2.429

Williams, R. R., Hunt, S. C., Hopkins, P. N., Stults, B. M., Wu, L. L., Hasstedt, S. J., & Barlow, G. K. (1993). Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah. American Journal of Hypertension, 6(11 Pt 2), 319S–327S. https://doi.org/10.1093/ajh/6.11.319s

---

Related Reading

• What Is Pharmacogenomics? — Learn how your genes affect drug response
• Familial Hypercholesterolemia and LDLR Genetics — Understanding genetic cholesterol disorders
• APOE4 and Alzheimer's Risk — Another critical cardiovascular risk gene
• CYP2C9 and Warfarin Pharmacogenomics — How genetics affects blood thinner dosing
• Fast vs. Slow Drug Metabolizers — Understanding your medication metabolism